This study aims to confirm the safety and efficacy of diazoxide as an additive to hyperkalemic cardioplegia in patients undergoing cardiac surgery with cardiopulmonary bypass. The investigators hypothesize that diazoxide combined with hyperkalemic cardioplegia provides superior myocardial protection and reduced myocardial stunning compared with standard cardioplegia alone. Thirty patients will receive treatment. Safety will be assessed by comparing mean arterial blood pressure measurements, glucose levels and incidence of adverse events between the two groups. Efficacy will be assessed by comparing right and left ventricular function in pre-operative vs post-operative transesophageal echocardiograms, need for mechanical circulatory support, ease of separation from bypass and Vasoactive Inotrope Score (VIS) between the two groups. The information gained could pave the way for the use of Katp (Potassium-atp) channel openers to prevent stunning, improve patient outcomes, and reduce health care costs related to myocardial stunning that requires inotropic and mechanical support following cardiac surgery.

开始日期2024-07-08

申办/合作机构

The Johns Hopkins University

TCTR20240731001 / Recruiting临床3期IIT

Scientific Title: Evaluation of the Clinical Efficacy and Safety of Dexmedetomidine Combined with Diazoxide for Anesthesia in Vaginal Ultrasound-Guided Egg Retrieval in IVF-ET Procedures

开始日期2024-07-01

申办/合作机构-

NCT05729282 / Recruiting临床1期IIT

Role of Hyperinsulinemia in Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis: Diazoxide Pilot & Feasibility Study

The goal of this clinical trial is to compare a two-week course of diazoxide (at two different doses) and placebo in people with overweight/obesity and insulin resistance (IR) with, or at high risk for, non-alcoholic fatty liver disease (NAFLD). The main questions it aims to answer are how mitigation of compensatory hyperinsulinemia with diazoxide affects parameters of glucose and lipid metabolism (how people with IR and NAFLD respond to lowering high insulin levels so that the investigators can see what happens to how the liver handles fat and sugar).
Participants will:
Take 27 doses of diazoxide (at 1 mg per kg of body weight per dose [mpk] or 2 mpk) or of placebo, over 14 days
Take 32 doses of heavy (deuterated) water (50 mL each) over 14 days
Have blood drawn and saliva collected after an overnight fast on four mornings over the two-week study period
Consume their total calculated daily caloric needs as divided into three meals per day
Wear a continuous glucose monitor for the two-week study period
Researchers will compare fasting blood tests at intervals during the study period in participants randomized (like the flip of a coin) to diazoxide 1 mpk, diazoxide 2 mpk, or placebo, to see how the drug treatment affects plasma glucose, serum insulin, and serum lipid parameters (triglycerides, free fatty acids, and apolipoprotein B). They will also consume heavy (deuterated) water to assess de novo lipogenesis (building of new fatty acids by the liver).

开始日期2023-08-01

申办/合作机构

Columbia University

[+1]

100 项与二氮嗪相关的临床结果

登录后查看更多信息

100 项与二氮嗪相关的转化医学

登录后查看更多信息

100 项与二氮嗪相关的专利（医药）

登录后查看更多信息

3,614

项与二氮嗪相关的文献（医药）

2024-03-01·Journal of diabetes investigation

Recurrent hypoglycemia induced by clopidogrel: A case report and mini review

Review

作者: Liu, Ye ; Hong, Tianpei ; Du, Weiguan ; Wang, Haining

Abstract:

This report describes a patient who developed recurrent hypoglycemia episodes after 23 days of antiplatelet therapy with clopidogrel for left subclavian artery stent implantation. The patient suffered from palpitation, profuse sweating and weakness on the 23rd day of clopidogrel treatment. The minimum plasma glucose was 2.2 mmol/L, and the hypoglycemia was associated with significantly elevated levels of insulin. A diagnosis of insulin autoimmune syndrome (IAS) was made with the presence of insulin autoantibody and a comprehensive differential diagnosis of other conditions related with hypoglycemia. Clopidogrel was stopped, and the patient was treated with acarbose and had frequent low‐carbohydrate meals; his hypoglycemia did not occur within 10 days. To date, seven cases of IAS induced by clopidogrel have been reported. Most reported cases were male aged in their 70s, and the hypoglycemic attack appeared 1–4 weeks after exposure to clopidogrel, characterized by severe hyperinsulinemia hypoglycemia with high titers of insulin autoantibodies. Most IAS cases can resolve spontaneously when they stop using the trigger medicine. Severe cases had been treated with drugs that reduce pancreatic insulin secretion (such as somatostatin and diazoxide), immunosuppressants (glucocorticoids, azathioprine and rituximab) and even immunoadsorption to remove the insulin autoantibody from the body. Considering the hypoglycemic attack might increase the risk of cardiovascular events among patients taking clopidogrel, we recommend that doctors should be aware of IAS as a rare severe adverse effect of clopidogrel, and be vigilant for the symptoms related with hypoglycemia in clopidogrel users.

2024-02-01·Clinical endocrinology

Commentary on studies investigating low‐dose diazoxide in hyperinsulinism

Article

作者: Huynh, Tony

2024-02-01·Clinical endocrinology

Low‐dose diazoxide is safe and effective in infants with transient hyperinsulinism

Article

作者: Dattani, Mehul ; Dastamani, Antonia ; Gilbert, Clare ; S, Athanasakopoulou ; Malhotra, Neha ; Morgan, Kate ; Yau, Daphne ; Cunjamalay, Annaruby ; Gunasekara, Buddhi

Abstract:

Objective:

Transient hyperinsulinism (THI) is the most common form of recurrent hypoglycaemia in neonates beyond the first week of life. Although self‐resolving, treatment can be required. Consensus guidelines recommend the lower end of the diazoxide 5–15 mg/kg/day range in THI to reduce the risk of adverse events. We sought to determine if doses <5 mg/kg/day of diazoxide can be effective in THI.

Design, Patients, Measurments:

Infants with THI (duration <6 months) were treated with low‐dose diazoxide from October 2015 to February 2021. Dosing was based on weight at diazoxide start: 2 mg/kg/day in infants 1000–2000 g (cohort 1), 3 mg/kg/day in those 2000–3500 g (cohort 2) and 5 mg/kg/day in those >3500 g.

Results:

A total of 73 infants with THI (77% male, 33% preterm, 52% small‐for‐gestational age) were commenced on diazoxide at a median age of 11 days (range 3–43) for a median duration of 4 months (0.3–6.8), with no difference between cohorts. The mean effective diazoxide dose was 3 mg/kg/day (range 1.5–10); 35% (26/73) required an increase from their starting dose, including 60% (9/15) of cohort 1. There was no association between perinatal stress risk factors or treatment‐related characteristics and dose increase. Adverse events occurred in 13 patients (18%); oedema (12%) and hyponatraemia (5%) were the most common. Two infants developed suspected necrotising enterocolitis (NEC); none had pulmonary hypertension.

Conclusion:

Diazoxide doses <5 mg/kg/day are effective in THI. While the nature of the association between diazoxide and NEC was unclear, other adverse events were mild. We suggest considering starting doses as low as 2–3 mg/kg/day in THI to balance the side effect risk while maintaining euglycaemia.

项与二氮嗪相关的新闻（医药）

2024-08-28

·Pharmaceutical Technology

Soleno wins FDA priority review for Prader-Willi therapy

The news also resulted in a modest increase in Soleno’s stock price; it was up by 6.3% when markets closed on 27 August. Credit: eamesBot / Shutterstock. The US Food and Drug Administration (FDA) is set to decide on whether to approve Soleno Therapeutics ’ lead therapy, diazoxide choline (DCCR), for treating hyperphagia associated with Prader-Willi syndrome, a rare genetic disorder. The regulatory agency has accepted the new drug application (NDA) for DCCR and has granted it priority review status . The priority status allows for various privileges including a faster approval process of six months, compared to the usual ten months. The FDA has also set a Prescription Drug User Fee Act (PDUFA) target action date of 27 December 2024. The agency has also announced its intention to hold an advisory committee (AdComm) meeting to “discuss the application for DCCR”. An AdComm is convened upon request of the FDA to review and evaluate the safety and efficacy data of a therapy. While the AdComm recommendations can affect a therapy’s FDA approval, its recommendations are non-binding, and the final decision is made by the FDA. The news also resulted in a modest increase in Soleno’s stock price; it was up by 6.3% when markets closed on 27 August after the news was released compared to the previous day. The company’s market cap currently stands at $1.9bn. See Also: Catalent gets grant for activated formylglycine-generating enzymes for protein production Novo Nordisk’s Wegovy sales weaken as Eli Lilly’s Zepbound exerts pressure DCCR is an extended-release tablet containing a crystalline salt formulation of diazoxide, an activator of the adenosine triphosphate (ATP)-sensitive potassium (KATP) channel. These channels are present in a variety of cells including pancreatic β cells, and adipocytes. The regulation of these cells can help manage hyperphagia, an excessive desire to eat, which is a hallmark of Prader-Willi syndrome. Soleno’s NDA is supported by data from five studies; a Phase I trial in healthy volunteers, three Phase II trials, and a Phase III trial. The placebo-controlled open-label Phase III DESTINY PWS study (NCT03440814) enrolled 125 participants with Prader-Willi syndrome aged four years or younger. After a year of follow-up, the trial met its primary endpoint by demonstrating significant improvements in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score. Greater improvements in HQ-CT scores were seen in patients with more severe baseline hyperphagia, with an HQ-CT score of over 22. Patients on DCCR also observed reductions in leptin, insulin, and insulin resistance, along with an increase in adiponectin. Soleno is also evaluating DCCR as a treatment for paediatric patients with genetic obesities, including SH2B1 deficiency obesity, obesity associated with PCSK1 mutation (rs6232 variant), and SIM1 deficiency obesity. The open-label Phase II trial (NCT05532020) is expected to enrol approximately 30 patients aged five years or younger suffering from either of the three genetic obesity disorders.

临床2期临床结果临床3期优先审批申请上市

2024-08-27

·药明康德

突破性小分子疗法获FDA优先审评资格；别构AKT抑制剂获得临床概念验证……

▎药明康德内容团队编辑小分子疗法获FDA优先审评资格 Soleno Therapeutics今天宣布，美国FDA已接受为其在研疗法DCCR缓释片递交的新药申请（NDA），用于治疗4岁及以上经基因检测确认的Prader-Willi综合征（PWS）患者的暴食症。FDA同时授予这一申请优先审评资格，预计在今年年底之前完成审评。DCCR是一款二氮嗪胆碱（diazoxide choline）缓释片剂，已经获得美国FDA授予的突破性疗法认定和快速通道资格，并在美国和欧盟获得孤儿药资格。 DCCR是一种含有二氮嗪胆碱的创新专有缓释剂型，每日口服一次。DCCR开发项目的数据支持来自五项在健康志愿者中完成的1期临床研究和3项完成的2期临床研究，其中一项是在PWS患者中进行的。在PWS的3期临床开发项目中，DCCR在解决PWS的标志性症状暴食症以及其他几种症状（如攻击性/破坏性行为、脂肪质量和其他代谢参数）方面显示出可喜的效果。别构AKT抑制剂概念验证临床试验获积极结果 Vaderis Therapeutics公司今日宣布，在研别构AKT抑制剂VAD044在治疗遗传性出血性毛细血管扩张症（Hereditary Haemorrhagic Telangiectasia，HHT）患者的随机双盲、安慰剂对照概念验证（POC）临床试验中取得了积极结果。 HHT是世界上第二常见的遗传性出血性疾病，常常导致严重的疾病负担、降低预期寿命和生活质量。尽管如此，目前全球范围内尚无获批的HHT治疗方法。Vaderis正在开发VAD044，这是一种口服、每日一次的别构AKT抑制剂。在这项双盲对照试验中，75名来自美国和欧洲的患者被随机分配接受安慰剂、30 mg或40 mg的VAD044治疗，为期12周。安全性是主要终点，VAD044在脱靶不良事件（AEs）的发生频率和严重程度上与安慰剂相似。与AKT通路抑制相关的不良事件大多为轻度、短暂并可在研究期间解决。几乎所有HHT患者都遭受不可预测、频繁且使人衰弱的鼻出血，这被认为是衡量整体HHT疾病活动和疾病负担的关键指标。在本研究中，VAD044在HHT的次要和探索性疗效终点上表现出剂量依赖性应答，包括关键的鼻出血终点。在12周治疗期结束时，接受40 mg剂量的患者在鼻出血频率、持续时间和无鼻出血天数方面均有临床意义的改善。为癌症患者发现靶向治疗选择，FDA批准Illumina癌症生物标志物检测 Illumina公司今天宣布，其体外诊断（IVD）产品TruSight Oncology（TSO）Comprehensive检测获得美国FDA的批准，并获得了首批两项伴随诊断（CDx）适应症的批准。该检测可分析超过500个基因，以对患者的实体瘤进行全面分析，从而提高识别免疫肿瘤学生物标志物或临床可操作性生物标志物的可能性，这些标志物可以用于指导靶向治疗的选择或帮助临床试验患者入组。 TSO Comprehensive已获FDA批准作为伴随诊断工具，识别携带神经营养性酪氨酸受体激酶（NTRK）基因融合的成人和儿童实体瘤患者，这些患者可能从拜耳公司的Vitrakvi（larotrectinib）治疗中受益。该检测还获批用于识别RET融合阳性的局部晚期或转移性非小细胞肺癌（NSCLC）成人患者，这些患者可能从礼来公司的Retevmo（selpercatinib）治疗中受益。新闻稿指出，大多数CDx测试通常仅针对一种类型的癌症，而TSO Comprehensive获得批准用于NTRK伴随诊断的所有实体瘤适应症，这有助于最大化每位患者活检中找到可针对信息的可能性。 ▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料： [1] Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome. Retrieved August 27, 2024, from https://www.globenewswire.com/news-release/2024/08/27/2936152/0/en/Soleno-Therapeutics-Announces-U-S-FDA-Acceptance-for-Filing-and-Priority-Review-of-NDA-for-DCCR-Diazoxide-Choline-Extended-Release-Tablets-in-Prader-Willi-Syndrome.html [2] Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT. Retrieved August 27, 2024, from https://www.prnewswire.com/news-releases/vaderis-announces-positive-clinical-proof-of-concept-trial-in-hht-302230320.html [3] FDA approves Illumina cancer biomarker test with two companion diagnostics to rapidly match patients to targeted therapies. Retrieved August 27, 2024, fromhttps://www.prnewswire.com/news-releases/fda-approves-illumina-cancer-biomarker-test-with-two-companion-diagnostics-to-rapidly-match-patients-to-targeted-therapies-302230979.html 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

优先审批临床2期孤儿药突破性疗法快速通道

2024-08-27

·GlobeNewswire-Health Care

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

PDUFA target action date set for December 27, 2024 FDA currently plans to hold an Advisory Committee meeting REDWOOD CITY, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for DCCR for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. The FDA granted Priority Review for the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 27, 2024. Priority review is designated to applications for drugs that, if approved, would provide a significant improvement in safety or effectiveness of the treatment, prevention or diagnosis of a serious condition. In its Priority Review Designation letter, the FDA also stated that it is currently planning to hold an advisory committee meeting to discuss the application for DCCR. “PWS is a devastating, rare condition that significantly impacts the lives of patients and their families,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno. “The FDA’s acceptance of our NDA is a significant milestone, and designating our application for priority review reaffirms that the FDA views PWS as a serious condition. We are immensely grateful to the entire PWS community, including patients, caregivers and advocacy groups, for their ongoing support. We remain committed to continuing to work closely with the FDA through the NDA review process.” Diazoxide choline has Breakthrough and Fast Track Designations in the U.S., as well as Orphan Drug Designation for PWS in the U.S. and E.U. About PWSThe Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The hallmark symptom of this disorder is hyperphagia, a chronic and life-threatening condition characterized by feelings of intense, persistent hunger, food pre-occupation, and an extreme drive to seek and consume food, which can severely diminish the quality of life for individuals with PWS and their families. Additional characteristics of PWS include behavioral problems, cognitive disabilities, low muscle tone, short stature (when not treated with growth hormone), the accumulation of excess body fat, developmental delays, and incomplete sexual development. Hyperphagia can lead to significant mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior) and longer term, co-morbidities such as diabetes, obesity, and cardiovascular disease. In a global survey conducted by the Foundation for Prader-Willi Research, 96.5% of respondents (parents and caregivers) rated hyperphagia and 92.9% rated body composition as either the most important or a very important symptom to be relieved by a new medicine. There are currently no approved therapies to treat the hyperphagia/appetite, metabolic, cognitive function, or behavioral aspects of the disorder. About DCCR (Diazoxide Choline) Extended-Release TabletsDCCR is a novel, proprietary extended-release dosage form containing diazoxide choline, the crystalline salt of diazoxide and is administered once-daily. The parent molecule, diazoxide, has been used for decades in thousands of individuals in a few rare diseases in neonates, infants, children and adults, but is not approved for use in PWS. Soleno conceived of and established extensive patent protection for the therapeutic use of diazoxide, diazoxide choline and DCCR in individuals with PWS. The DCCR development program is supported by data from five completed Phase 1 clinical studies in healthy volunteers and three completed Phase 2 clinical studies, one of which was in individuals with PWS. In the PWS Phase 3 clinical development program, DCCR showed promise in addressing hyperphagia, the hallmark symptom of PWS, as well as several other symptoms such as aggressive/destructive behaviors, fat mass and other metabolic parameters. About Soleno Therapeutics, Inc.Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the timing of any regulatory process or ultimate approvals and determining a path forward for DCCR for the treatment of PWS. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with the FDA’s review of our NDA, market conditions, as well as risks and uncertainties inherent in Soleno’s business, including those described in the company's prior press releases and in the periodic reports it files with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Corporate Contact:Brian RitchieLifeSci Advisors, LLC212-915-2578

临床2期申请上市优先审批临床3期快速通道

100 项与二氮嗪相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00294	二氮嗪	V03AH01 C02DA01	DB01119

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高血压	美国	Schering Corp.	1973-01-22
低血糖	美国	Schering Corp.	1973-01-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESPE2022	N/A	血色素沉着症	99	Diazoxide 2mg/kg/day	範簾獵醖築鏇範齋範醖(糧鹽壓積餘簾窪窪簾簾) = Adverse events can still be observed with DZX low doses, but at a lower incidence compared to the STD 齋蓋夢築壓製鹽獵衊鑰 (鑰鹹憲顧膚網廠艱衊艱 ) 更多	积极	2022-09-15
				Diazoxide 3mg/kg/day
ESPE2022	N/A	先天性高胰岛素血症 HADH mutation	-	Diazoxide	顧築網鏇鏇糧製範繭淵(製艱網衊範衊醖積醖夢) = 餘憲壓繭鬱鏇膚衊獵醖選壓夢鏇獵簾願襯膚網 (繭願憲廠鏇鹽願獵醖膚, 0.9 ~ 7.1) 更多	-	2022-09-15
				Diazoxide	製餘壓餘觸積選餘艱窪(鹽壓網餘夢淵構餘鑰蓋) = 夢艱獵鬱夢齋製壓艱夢顧醖襯蓋襯膚簾範齋願 (鑰範窪襯簾鬱選襯顧蓋 )
ESPE2019	N/A	先天性高胰岛素血症	-	Diazoxide	醖廠糧膚夢鹹淵蓋廠廠(齋獵憲構糧廠獵襯壓選) = 製觸願醖製鏇構繭簾鬱齋鏇糧遞鑰蓋壓夢窪繭 (憲壓選衊夢繭鏇夢衊積 )	-	2019-09-19
				Octreotide	醖廠糧膚夢鹹淵蓋廠廠(齋獵憲構糧廠獵襯壓選) = 積艱艱衊鹽願鏇選顧艱齋鏇糧遞鑰蓋壓夢窪繭 (憲壓選衊夢繭鏇夢衊積 )
ESPE2019	N/A	先天性高胰岛素血症 ABCC8 \| KCNJ11	-	Diazoxide	鬱鹽遞遞糧糧網蓋糧築(鏇鏇獵鏇艱鹽鑰醖糧窪) = due to vomiting on oral feeds 淵夢顧積鹹簾網襯鏇廠 (觸糧淵廠窪夢蓋壓範襯 ) 更多	-	2019-09-19
ESPE2018	N/A	先天性高胰岛素血症	-	Diazoxide	顧鹹鹽窪夢繭艱鏇選鹽(壓蓋壓鑰簾積餘齋淵鑰) = Our patient is homozygote for this mutation and both his parents are heterozygote, confirming the diagnosis of autosomal recessive congenital hyperinsulinism. Now aged 5 years, the patient shows good glycaemic control on octreotide in combination with frequent feeding. However, he has developmental delay with epilepsy, requiring multiple anti-convulsivant drugs. 窪製夢鹹襯簾簾齋積遞 (壓製鬱網鬱鏇淵衊製願 )	-	2018-09-27
NCT00631033 (Pubmed \| J Clin Endocrinol Metab)	临床2期	肥胖	51	Diazoxide	築窪願艱糧遞夢築積製(鹹積選築製窪鏇鹽築廠) = 11 淵淵網艱鹽衊鏇網廠窪 (遞鏇範醖艱艱範餘鬱繭 ) 更多	-	2018-06-01
				Placebo
NCT02049385 (CTgov)	临床1/2期	重度抑郁症	10	Diazoxide (Diazoxide)	顧壓蓋顧顧餘糧齋廠獵(襯窪夢醖襯夢築窪網齋) = 襯選淵遞壓構願窪糧膚簾鹽壓願鏇遞鹽鹽襯淵 (窪鬱願壓願壓獵憲廠築, 網淵衊襯廠餘餘鹽壓衊 ~ 網遞餘鑰襯繭選壓願廠) 更多	-	2017-10-13
				Placebo (Placebo)	顧壓蓋顧顧餘糧齋廠獵(襯窪夢醖襯夢築窪網齋) = 顧遞憲遞鏇醖窪壓製憲簾鹽壓願鏇遞鹽鹽襯淵 (窪鬱願壓願壓獵憲廠築, 夢齋鏇糧選醖顧窪襯積 ~ 襯夢願齋膚鬱繭觸鹽襯) 更多
NCT00306683 (PEDIAC, Pubmed \| J Clin Endocrinol Metab)	临床3期	肥胖	40	Diazoxide	蓋簾積醖願繭積遞願獵(鹹壓艱壓築淵齋壓壓鹽) = 選遞餘選壓餘範膚窪築觸積廠繭鹹積觸選願網 (簾鑰壓鹽鏇窪鬱願艱鹹 )	不佳	2016-12-01
				Placebo	蓋簾積醖願繭積遞願獵(鹹壓艱壓築淵齋壓壓鹽) = 糧鏇構範衊鑰製願積築觸積廠繭鹹積觸選願網 (簾鑰壓鹽鏇窪鬱願艱鹹 )
ESPE2016	N/A	胎儿生长受限 \| 先天性高胰岛素血症 ABCC8 \| KCNJ11 \| GLUD1 ... 更多	-	Fetal diazoxide exposure	醖糧鬱廠鏇願觸觸繭艱(積壓鹽築醖窪繭蓋鏇鬱) = 築繭積繭衊簾願構廠淵齋構觸窪製糧糧鏇醖鹽 (齋襯觸構網膚醖繭鬱膚 )	-	2016-09-10
NCT00683774 (CTgov)	N/A	多囊卵巢综合征	21	diazoxide (PCOS Subjects)	艱鹽構網廠觸窪齋廠製(餘願構醖艱願網餘鏇窪) = 淵築選蓋齋淵觸構範蓋蓋觸衊壓範膚艱構糧憲 (鬱襯選顧願蓋淵膚繭鹽, 膚艱淵醖築膚鬱選鬱襯 ~ 襯選餘廠鏇獵製簾遞鏇) 更多	-	2014-08-21
				diazoxide (Normal Subjects)	艱鹽構網廠觸窪齋廠製(餘願構醖艱願網餘鏇窪) = 鬱簾網選積齋衊顧願構蓋觸衊壓範膚艱構糧憲 (鬱襯選顧願蓋淵膚繭鹽, 壓鹹壓鬱簾願顧願鏇艱 ~ 積範築窪簾廠餘鑰夢醖) 更多